|Mr. David Moatazedi||Pres, CEO & Director||1.25M||N/A||1978|
|Ms. Lauren P. Silvernail||CFO & Exec. VP of Corp. Devel.||633.18k||N/A||1958|
|Dr. Rui Avelar Dip.SportMed, M.D., C.CFP||Chief Medical Officer and Head of R&D||631.26k||N/A||1962|
|Mr. Ashwin K. Agarwal||VP of Fin., Investor Relations & Treasury||N/A||N/A||N/A|
|Mr. Jeffrey J. Plumer||Gen. Counsel||N/A||N/A||N/A|
|Mr. Kurt Knab||VP of Sales||N/A||N/A||N/A|
|Ms. Crystal Muilenburg||Chief Marketing Officer||N/A||N/A||1980|
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.
Evolus, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 8; Compensation: 7.